Filing Flows

Filing Flows › Companies › Prime Medicine › Cash flow

Prime Medicine cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$41.1M in Q2 2026 · −$157M over twelve months

Operating cash flow−$41.0M
Capital spending−$46K
Free cash flow−$41.1M

Analysis

In Q2 2026, Prime Medicine generated −$41.0M of operating cash flow and spent $46K on capital projects, leaving free cash flow of −$41.1M. That is $1.9M more than in Q2 2025 (−$43.0M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$156M; the largest uses were operating cash flow ($156M), capital spending ($797K); besides operations, cash came from other financing ($145M), other investing ($4.4M); the cash balance fell by $6.4M.

Operating cash flow was −$41.0M against net income of −$42.1M. The largest differences: payables −$6.5M, stock-based pay +$4.9M, depreciation & amortization +$1.8M.

Free cash flow

Prime Medicine: free cash flow by quarterPrime Medicine: free cash flow by quarter−$27.2MQ3 2024$14.5MQ4 2024−$51.3MQ1 2025−$43.0MQ2 2025−$35.3MQ3 2025−$37.5MQ4 2025−$42.9MQ1 2026−$41.1MQ2 2026
Operating cash flow less capital spending.
Prime Medicine: operating cash flow against capital spendingPrime Medicine: operating cash flow against capital spendingOperating cash flowCapital spending−$25.9M$1.3MQ3 2024$16.2M$1.8MQ4 2024−$48.9M$2.4MQ1 2025−$41.4M$1.6MQ2 2025−$35.0M$247KQ3 2025−$37.3M$290KQ4 2025−$42.7M$214KQ1 2026−$41.0M$46KQ2 2026
Latest (Q2 2026): Operating cash flow −$41.0M, Capital spending $46K.

Capital allocation, year by year

Prime Medicine: where the cash came from (up) and went (down), by fiscal yearPrime Medicine: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2021: Operating cash flow −$34.1MFY2021: Capital spending −$4.2MFY2021FY2022: Operating cash flow −$132MFY2022: Shares issued $186MFY2022: Capital spending −$16.1M$186MFY2022FY2023: Operating cash flow −$165MFY2023: Shares issued $655KFY2023: Capital spending −$8.7M$655KFY2023FY2024: Operating cash flow −$123MFY2024: Shares issued $38.2MFY2024: Capital spending −$7.3M$38.2MFY2024FY2025: Operating cash flow −$163MFY2025: Shares issued $781KFY2025: Capital spending −$4.5M$781KFY2025
Over these 5 years operating cash flow totalled −$617M; the largest uses were operating cash flow ($617M) and capital spending ($40.8M). Cash-flow statements as filed.

Where the cash came from and went

Prime Medicine: sources (+) and uses (−) of cash, Q2 2026Prime Medicine: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$41.0MOther investing$24.1MCash drawn (+) / kept (−)$16.7MOther financing$338KCapital spending−$46KShares issued$23K
Prime Medicine: sources (+) and uses (−) of cash, TTM to Q2 2026Prime Medicine: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$156MOther financing$145MCash drawn (+) / kept (−)$6.4MOther investing$4.4MShares issued$1.2MCapital spending−$797K

From profit to cash

Prime Medicine: net income to operating cash flow, Q2 2026Prime Medicine: net income to operating cash flow, Q2 2026Net income−$42.1MDepreciation & amortization$1.8MStock-based pay$4.9MPayables−$6.5MAccrued liabilities$880KDeferred revenue−$1.1MPrepaid and other assets$659KOperating cash flow−$41.0M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$41.0M−$46K$23K$16.7M−$41.1M
Q1 2026−$42.7M−$214K$393K−$1.1M−$42.9M
Q4 2025−$37.3M−$290K$408K$8.4M−$37.5M
Q3 2025−$35.0M−$247K$373K−$17.6M−$35.3M
Q2 2025−$41.4M−$1.6M—$38.4M−$43.0M
Q1 2025−$48.9M−$2.4M—$90.6M−$51.3M
Q4 2024$16.2M−$1.8M—−$64.5M$14.5M
Q3 2024−$25.9M−$1.3M$32K−$62.9M−$27.2M

Prime Medicine: income statement and cash flow

Prime Medicine, Q4 2025: revenue $838K (-62% year over year). The chart follows the revenue to costs, profit and cash.

Prime Medicine: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.